Clinical Trials

Status
Published

1456 Results

Open
Phase
III
SWOG Clinical Trial Number
CTSU/NRG-BR004

A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer

Status Notes
Activated by NRG Oncology on 3/12/19.
Activated by SWOG: 7/24/2019
Research Committee(s)
Breast Cancer
Activated
07-24-2019
ClinicalTrials.gov Registry Number
NCT03199885
Open
Phase
SWOG Clinical Trial Number
CTSU/A011202

A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

Status Notes
ALLIANCE activated: 2/7/14
SWOG activated: 7/24/19
Research Committee(s)
Breast Cancer
Activated
07-24-2019
ClinicalTrials.gov Registry Number
NCT01901094
Open
SWOG Clinical Trial Number
CTSU/A221405

A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women with Endocrine Responsive Breast Cancer who Desire Pregnancy

Status Notes
Alliance activated: 10/15/15
SWOG activated: 7/27/19
Research Committee(s)
Breast Cancer
Activated
07-24-2019
ClinicalTrials.gov Registry Number
NCT02308085
Open
Phase
SWOG Clinical Trial Number
CTSU/EA1131

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Breast Cancer following Neoadjuvant Chemotherapy

Status Notes
ECOG-ACRIN activated: 4/29/2015
SWOG activated: 7/24/19
Research Committee(s)
Breast Cancer
Activated
07-24-2019
ClinicalTrials.gov Registry Number
NCT02445391
Open
Phase
SWOG Clinical Trial Number
CTSU/EA1151

Tomosynthesis Mammographic Imaging Screening Trial (TMIST)

Status Notes
ECOG-ACRIN Cancer Research Group activated: 7/6/17
SWOG activated: 7/24/19
Research Committee(s)
Breast Cancer
Activated
07-24-2019
ClinicalTrials.gov Registry Number
NCT03233191
Open
Phase
SWOG Clinical Trial Number
CTSU/NSABP-B-51
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-BR002

A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer

Status Notes
Activated by NRG Oncology on 12/24/2014.
Activated by SWOG: 7/19/2019
Research Committee(s)
Breast Cancer
Activated
07-19-2019
ClinicalTrials.gov Registry Number
NCT02364557
Open
Phase
Accrual
0%
SWOG Clinical Trial Number
S1826

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Status Notes
Activation - Effective 7/19/19
Research Committee(s)
Lymphoma
Activated
07-19-2019
ClinicalTrials.gov Registry Number
03907488
Open
Phase
Accrual
0%
Open
Accrual
0%
SWOG Clinical Trial Number
S1916

Feasibility of a Digital Medicine Program in Optimizing Opioid Pain Control in Cancer Patients

Status Notes
This is being distributed for IRB review only.
Research Committee(s)
Cancer Care Delivery
Activated
06-11-2019
Open
SWOG Clinical Trial Number
CTSU/NHLBI-MDS

The National Myelodysplastic Syndromes (MDS) Study

Research Committee(s)
Prevention & Epidemiology
Leukemia
Activated
06-01-2019
ClinicalTrials.gov Registry Number
NCT02775383
Open
Accrual
12%
SWOG Clinical Trial Number
S1800A

A PHASE II RANDOMIZED STUDY OF RAMUCIRUMAB PLUS MK3475 (PEMBROLIZUMAB) VERSUS STANDARD OF CARE FOR PATIENTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER (LUNG-MAP NON-MATCHED SUB-STUDY)

Status Notes
S1800A will open to accrual May 17, 2019, effective 11:00 am PST.

This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
Lung Cancer
Activated
05-17-2019
Open
Phase
III
Accrual
1%
SWOG Clinical Trial Number
S1806
Open
Phase
Accrual
3%
SWOG Clinical Trial Number
S1714

A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients

Status Notes
This study is active as of 3/1/19.
Research Committee(s)
Symptom Control and Quality of Life
Breast Cancer
Lung Cancer
Early Therapeutics & Rare Cancers
Activated
03-01-2019
Open
Phase
SWOG Clinical Trial Number
CTSU/EAE161

Perfusion CT to Predict Progression-free Survival and Response Rate in Bevacizumab and Paclitaxel Treatment of Platinum-Resistant Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Peritoneal Carcinoma

Status Notes
SWOG Activated/Championed CTSU/EAE161, effective March 1, 2019
Research Committee(s)
Early Therapeutics & Rare Cancers
Activated
03-01-2019
ClinicalTrials.gov Registry Number
NCT03412630
Open
Phase
III
Accrual
6%
SWOG Clinical Trial Number
S1600

A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes

Status Notes
This study is open effective February 21, 2019 at 2:00 p.m. Eastern.
Research Committee(s)
Symptom Control and Quality of Life
Genitourinary Cancer
Activated
02-21-2019
ClinicalTrials.gov Registry Number
NCT03757949
Open
Accrual
0%
SWOG Clinical Trial Number
S1614

Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Cytotoxic Therapy for Solid Tumors

Status Notes
Active 2/21/19
Research Committee(s)
Symptom Control and Quality of Life
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Lung Cancer
Melanoma
Activated
02-21-2019
ClinicalTrials.gov Registry Number
03887702
Open
SWOG Clinical Trial Number
LUNGMAP

A MASTER PROTOCOL TO EVALUATE BIOMARKER-DRIVEN THERAPIES AND IMMUNOTHERAPIES IN PREVIOUSLY-TREATED NON-SMALL CELL LUNG CANCER (Lung-MAP Screening Study)

Status Notes
LUNGMAP will open to accrual January 28, 2019, effective 2:00 pm PST.

This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
Lung Cancer
Activated
01-28-2019
ClinicalTrials.gov Registry Number
NCT03851445
Open
SWOG Clinical Trial Number
S1900BDSS

S1900 Biomarker-Driven Sub-Study Version Control Protocol (S1900BDSS VCP)

Status Notes
The LUNGMAP S1900 Biomarker-Driven Sub-Study Version Control Protocol (S1900BDSS) is active effective 1/28/19.

The intent of the S1900BDSS is to allow an individual sub-study to be revised independently of the other sub-studies. The S1900BDSS keeps track of revisions made to various S1900 biomarker-driven sub-studies of LUNGMAP and their component documents over the course of the overarching Lung-MAP study, and lists the version date of each revision.

Sites may use this document to verify the most current version of a LUNGMAP S1900 biomarker-driven sub-study, and may also reference this document for an overview of S1900 sub-study revisions.
Research Committee(s)
Lung Cancer
Activated
01-28-2019